Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Blog | May 28, 2020

Minnesota Patent Litigation Wrap-Up — April 2020

Blog | May 19, 2020

Minnesota Patent Litigation Wrap-Up — Q1 2020

Blog | May 14, 2020

Minnesota Patent Litigation Wrap-Up — Q4 2019

Blog | May 12, 2020

Prodrugs — Federal Circuit Holds That A PTE Does Not Cover Their Metabolites

Blog | May 04, 2020

EDTX Monthly Wrap-Up — April 2020

Blog | April 20, 2020

A Biosimilar's Guide to the BPCIA Patent Dance: Five Key Questions for Every Biosimilar Applicant to Consider

Blog | April 14, 2020

Federal Circuit Rules No "Prevailing Party" for Attorneys' Fees under § 285 after Plaintiff's Voluntary Dismissal — Even Where Defendant Invalidates Patent-in-Suit

Blog | April 02, 2020

Section 101: Cert. Denied ... Now What?

Blog | March 31, 2020

EDTX Monthly Wrap-Up March 2020

Blog | March 20, 2020

Insulin and Other Biological Products Previously Regulated as "Drugs" Transition to Biologics Regulation on March 23, 2020

Blog | March 19, 2020

Autonomous Vehicles Q&A

Blog | March 12, 2020

Massachusetts Patent Litigation Wrap Up — August 2019